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Treatment  of normally  tumorigenic  murine  tumor  cell  lines  in  vitro  with 
chemical  mutagens  followed  by  cloning of the  surviving cells,  results  in  the 
selection, at extraordinarily high frequencies (anywhere from <1% to >90%), of 
clones unable to grow progressively in normal syngeneic mice (1-7). Such clones, 
which are  phenotypically stable  in  culture over a  period  of several  weeks  or 
months, have been designated by Boon and his colleagues (1-6) as "tum-" (non- 
tumorigenic in  normal  hosts). ~ They  have  been  derived  using such  standard 
mutagens as N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)  and  ethyl  meth- 
anesulfonate (EMS), from at least eight different murine tumors of viral, chem- 
ical, or spontaneous origin (1-7).  Because the turn- clones will grow readily in 
highly immunosuppressed recipients, e.g., X-irradiated or nude mice (1-8),  the 
turn-  phenotype appears  to  have  an  underlying immunological basis,  a  view 
confirmed by detailed in vitro studies of T  cell-mediated cytotoxicity (CMC). 
These studies have also shown that each turn- clone derived from a particular 
mutagenized parent  line possesses an individual tumor-specific antigen distinct 
from the new antigen found on any other turn- clone, i.e., there is a  startling 
degree of tumor antigen polymorphism (1-7).  Of considerable interest  is that 
this holds true even for totally non-immunogenic tumors of spontaneous origin 
(5-7)  and as such,  has very broad and  important implications for the field of 
tumor immunology, especially in relation to the controversies surrounding the 
antigenic and immunologic status of neoplastic cells (9-11).  Nevertheless, very 
little is known about how mutagens can cause such drastic and heritable changes 
in the behavioral  properties  of tumors in  vivo,  and at  such  high frequencies. 
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However, because these frequency rates are many orders of magnitude greater 
than  that  predicted  by  classic  genetic  (point)  mutational  events,  there  is  the 
distinct possibility that an  "epigenetic" mechanism is involved.  By "epigenetic" 
we mean a heritable phenotypic change brought about by a mechanism that does 
not  involve a  change  in  the  actual  sequence  of nucleotides  in  DNA.  Such  a 
change can be brought about by "DNA hypomethylation." 
Many investigators (reviewed in references  12 and  13) have reported that a 
drop in the level of 5-methylcytosine in DNA can result in expression of genes 
that were previously "silent." Such  DNA  hypomethylation can be achieved by 
the treatment of cells with the  DNA  hypomethylating agent  5-azacytidine, an 
analogue of the DNA base, cytosine. This can result in high frequency phenotypic 
alterations (in  the  order  of 10%)  as a  result of alteration in  gene  expression. 
Furthermore,  the  altered  methylation patterns  and  levels  can  be  somatically 
inherited  (12,  13),  though  not  with  perfect  fidelity (14),  thereby  raising  the 
distinct possibility that "methylation changes can masquerade as mutations" (13). 
Finally, a number of investigators have reported that many mutagens (including 
EMS  and  MNNG)  and  carcinogens  can  themselves cause  hypomethylation of 
DNA  (13,  15-17).  It  therefore  seemed  reasonable  to  hypothesize that  hypo- 
methylation of DNA could explain the high frequency at which the turn- clones 
are generated after mutagen treatment. We therefore decided to test the tumor- 
igenic and immunologic properties of tumor cell clones that had been pretreated 
with EMS or 5-azacytidine. The results demonstrate that 5-azacytidine can cause 
virtually the same changes as EMS, despite an absence of any significant muta- 
genic effect in the treated cells. 
Materials and Methods 
Animals.  DBA/2 and A/J strain mice 5-6 wk old, were purchased from The Jackson 
Laboratory, Bar  Harbor,  ME.  BALB/c-nu/nu  mouse  breeding pairs  were  originally 
obtained from the National Institutes of Health (NIH) and are currently maintained in a 
nude mouse colony established in  the research  facilities  of the  Long Beach Veterans 
Administration Hospital. In all experiments aimed at assessing the growth potential of 
turn-  variants,  both  nu/nu and  nu/+  heterozygous littermates were  challenged with 
tumor. 
Tumors.  The origin and characteristics of the MDAY-D2 tumor have been described 
in detail elsewhere (18,  19). The P815 mastocytoma was obtained from Dr. R. Herberman 
(NIH). The TA3 mammary adenocarcinoma was obtained through Dr. Joseph G. Mayo, 
NIH, and Dr. Arthur Bodgen, Mason Research Institute Tumor Bank, Worcester, MA. 
Tumor cells were maintained in culture or by weekly intraperitoneai passage. All cell lines 
were routinely tested to assure that they were free of Mycoplasma by Dr. Eric Stanbridge 
(Department of Microbiology, UCLA/Irvine). Only Mycoplasma-free cell lines were used 
in these studies. 
Treatment of Cells with Mutagens.  Treatment of tumor cells with MNNG was performed 
according to the methods of Boon et al. (1-6). Cells (3 x  106 in 5 ml) were exposed to 
MNNG at 3 #g/ml for 60 min. The cells were washed and placed in culture. Treatment 
with EMS was according to the method of Gillin et al. (20). 5 ml of tumor cells at 6 X 105 
cells/ml were placed in small, sterile petri dishes and allowed to equilibrate to a 5% CO2 
atmosphere in RPMI without fetal calf serum. After 1 h, 2.5 ILl (360 pg/ml) of EMS was 
added, and the cells were allowed to incubate for 2 h, after which they were centrifuged 
and incubated in RPMI medium with 10% fetal calf serum. Under these conditions, cell 
viability is reduced to ~30% after 24 h. This is consistent with the findings of others (1- 
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Treatment of Cells with 5-Azacytidine.  Treatment  with  5-azacytidine  was  performed 
according to  the  method of P. Jones  (personal  communication).  5-Azacytidine (final 
concentration: 3 #M) was added to 5 ml of cells at 6 ×  105 cells/ml. The cells were washed 
after 24 h incubation and allowed to re-grow for 1 wk before cloning. Cell viabilities after 
5-azacytidine treatment  generally exceeded 90%.  After cloning,  cells  from individual 
clones were injected subcutaneously (5  ×  105 cells) into syngeneic mouse hosts. Clones 
that failed to grow were tested again, i.e., they were reinjected into normal syngeneic 
hosts twice more to assess  the stability of the tum- phenotype. In addition, individual 
tum- clones were injected into nude mice and each was also assessed  for its ability to 
protect against a parent tumor challenge and to induce a cytotoxic T  lymphocyte (CTL) 
response. 
Assessment ofT Cell Cytotoxicity.  A standard method to induce secondary CTL responses 
was used which involves in vitro restimulation (7,  18). Three DBA/2 or A/J strain mice 
were given subcutaneous injections of 5 ×  10  ~ cells from each of the P815-5-azacytidine- 
induced  tum-  clones  (J  or  D)  or  TA3-5-azacytidine-induced turn-  clones  (K  or  P), 
respectively. 14 d later, the spleens were removed, pooled, and restimulated in vitro with 
mitomycin C-treated cells identical to the initial priming clone. 5 d later, the cells were 
harvested and used as effectors against different targets, in an nlIndium release assay (18). 
Assessment of Mutagenic Potential of EMS vs. 5-Azacytidine.  Cells treated with EMS or 5- 
azacytidine above were assessed for the number of induced ouabain-resistant (Oua  R) 6- 
thioguanine-resistant (6-TG  r) or 2-deoxy-D-galactose-resistant  (2-D-gal  r) colonies as follows. 
For each experiment, 4.8 ×  106 tumor cells from various tumor lines were plated into 96- 
well microtiter plates (each well containing 104 cells in 200 #1 of culture medium) in the 
presence of either 3 mM ouabain, 10  -4 M 6-thioguanine, or 3 mM 2-deoxygalactose. The 
number of drug-resistant colonies was determined 11-14 d later. 
Assessment of DNA  5-Methylcytosine Content by High Performance Liquid  Chromatography 
(HPLC).  The  HPLC  method used  to  quantitate  5-methylcytosine was  based  on  that 
described by Flateau et al. (21). Cells were labeled with [6-'H]-uridine by incubating 2 × 
105 cells/ml with 2 #Ci/ml uridine. A Beckman HPLC system with a Altex ULTRASIL- 
CX column was used with isocratic elution using 0.035 M KH2PO4, pH 2.5 containing 
5% vol/vol MeOH at a flow rate of 2.5/min. The elution of the bases was measured using 
known standards.  The fractions containing the cytosine (C) and 5-methylcytosine (MC) 
were assayed for radioactivity by scintillation counting. Percentage MC (21) was calculated 
as follows:  % MC = cpm (MC)/cpm (C) + cpm (MC) ×  100%. 
Results 
Frequency  of Selection of Turn- Clones.  Three different tumors treated with 5- 
azacytidine were cloned and  assessed  for the  turn- phenotype, and  the results 
compared to those obtained using conventional mutagens (MNNG or EMS) with 
the same tumors.  The frequency of selection of rum- variants derived after 5- 
azacytidine treatment  (and  compared to frequencies seen after mutagen  treat- 
ment)  is  shown  in  Table  I.  15  randomly  selected tum-  variants  of TA3  were 
reinjected into A/J mice or BALB/c nude mice on two subsequent occasions.  14 
of these  clones  retained  their  tum-  phenotype.  Of  these  14  clones,  4  were 
injected an additional  four times over a  six-month period and remained stable 
for their turn- phenotypes. Of these four, however, only one has remained turn- 
after nine months in culture. No turn- MDAY-D2 clones were detected after 5- 
azacytidine treatment.  This  is  identical  to  what  was  observed  when  the  same 
tumor  was  treated  once  with  EMS  or  MNNG  as  shown  in  Table  I,  and  as 
described previously. Tum-  variants from MDAY-D2  could be generated,  but 
only at  low frequency after a  double (sequential)  treatment  with the  mutagen 
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TABLE  I 
Frequency of Turn- Variant Selection after Mutagen or 5-Amcytidine Treatment 
Tumor line tested 
Frequency of tum- clones after treatment in 
vitro with*: 
EMS  MNNG  5-Azacytidine 
Growth of 
tum- clones 
in nude 
mice 
TA3 Adenocarcinoma  26/28  23/24  108/124  8/8 
(>90%)  (>00%)  (87%) 
MDAY-D2 (undifferentiated  0/180  3/24  0/124  3/3 
tumor)  (0%)  (12.5%)  (0%) 
P815 Mastocytoma  0/40  0/40  4/24  4/4 
(0%)  (0%)  (16.7%) 
* Tumor cells were treated with mutagens (EMS or MNNG) or 5-azacytidine,  and cloned by 
limiting dilution. 5 x  10  ~ cells from individual clones were injected subcutaneously, into 
syngeneic  mice and their growth assessed. Randomly  selected turn- clones were also injected 
subcutaneously  into nude mice and observed for growth. 
MDAY-D2 turn- variants. All four tum- P815 clones that were isolated after 5- 
azacytidine  treatment  retained  their  turn-  phenotype  after  three  months  in 
culture. 
Immunogenicity of Turn- Clones Derived after 5-Azacytidine Treatment.  In order to 
demonstrate that the failure of turn- clones to grow was due to an immunological 
change,  eight  of the  TA3  and  four of the  P815  5-azacytidine-induced tum- 
clones  were  injected  into  T  ceil-deficient  athymic (nude)  mice.  All  of these 
clones, which failed to grow in syngeneic normal animals, grew progressively and 
killed the nude mouse host. Furthermore, all TA3 5-azacytidine-induced turn- 
clones (N =  23) and P815 5-azacytidine-induced turn- clones (N =  4) were able 
to protect syngeneic hosts against challenge with the parent tumor.  Thus  A/J 
strain  mice  preimmunized  with  individual  TA3  5-azacytidine-induced  turn- 
clones and subsequently challenged with ordinarily lethal doses of TA3  tumor 
cells have survived indefinitely (>10 months) without evidence of tumor recurr- 
ence. Furthermore, this protection was specific in that animals immunized with 
a  5-azacytidine-induced  turn-  clones  of TA3,  were  not  protected  against  a 
subsequent  challenge with an  unrelated  A  strain  tumor,  i.e.,  the  H6TBJ-750 
hepatoma (data not shown). 
All the 5-azacytidine-induced turn- variants tested (for TA3 N  -- 6; for P815 
N =  4) were able to induce CTL response after appropriate secondary stimulation 
(Table II). While this response was sometimes less than that seen with EMS- or 
MNNG-derived  turn-  clones  (7),  it  was  far greater  than  that  seen  in  animals 
injected with the parent tumor (Table II). In addition, as noted above, this CTL 
response was sufficient for the specific protection against parent tumor challenge 
in vivo. 
Evidence That 5-Azacytidine Is Not Mutagenic in Murine Tumor Cells.  It is evident, 
from these experiments,  that  5-azacytidine, which has been  shown to be  non- 
mutagenic,  or  very  poorly  so,  in  non-neoplastic  mouse  C3H  10TI/2  cells  or 
Chinese hamster lung (V79)  cells (22)  is as effective in selecting immunogenic 
turn- variants as EMS or MNNG (or as ineffective, in the case of MDAY-D2). 
Because the mutagenic effects of 5-azacytidine on mouse tumor lines have not 
yet been assessed, we tested its effect on the frequency of drug-resistant mutants FROST  ET  AL. 
TABLE  II 
Cytotoxic T Cell Responses Generated  by 5-Azacytidine  Selected Turn- 
Clones* 
1495 
% Cytotoxicity at 
Mice immunized with:  Targets  50/1 E/T Ratio 
TA3-clone K  TA3-clone K  32 ±  1.4 
TA3-clone K  TA3-clone P  38 ±  2.1 
TA3-clone K  TA3 (parent)  27 ±  1.6 
TA3-clone P  TA3-clone P  37 +  0.8 
TA3-clone P  TA3-clone K  39 ±  0.6 
TA3-clone P  TA3-(parent)  28 ±  1.2 
TA3 (parent)  TA3-(parent)  <5% 
TA3 (parent)  TA3-clone K  0 
TA3 (parent)  TA3-clone P  0 
P815-clone J  P815-clone J  100 
P815-clone J  P815-clone D  90 +  2.4 
P815-clone J  P815-(parent)  85 ±  1.6 
P815-clone D  P815-clone D  83 +  3.1 
P815-clone D  P815-cloneJ  56 ±  0.8 
P815-clone D  P815 (parent)  73 +  1.4 
P815 (parent)  P815 (parent)  <5% 
* Two tum- clones from TA3 and P815 were injected subcutaneously into 
syngeneic hosts from which the spleens were removed 14 d later. Spleen 
cells were restimulated with mitomycin C-treated tumor cells identical 
to the priming clone. 5  d  later the spleen cells were used as effectors 
against various targets,  Control mice were immunized with cells from 
the untreated parent tumor. 
TABLE  III 
Frequency of Oua  n, 6-TG r, and 2-D-gaU Mutants Obtained  after Treatment of MDAY-D2 or 
TA3 Tumor Cells In Vitro with 5-Azacytidine  or EMS 
Cell line  Treatment* 
No. of drug  x colonies/10  s cells 
10 -4 M 
3 mM 2-Deoxy-  3 mM Ouabain  6-Thio- 
guanine  galactose 
MDAY-D2  No treatment  0  8  0 
MDAY-D2  3 #M 5-azacytidine  0.2  8  0.3 
MDAY-D2  360 #g/ml EMS  29  70  10 
TA3  No treatment  0  0  ND 
TA3  3 #M 5-azacytidine  1  0  ND 
TA3  360 t~g/ml EMS  15  1.3  ND 
* Treatments were for 24 h,  in complete medium and cells were plated 4-6 d  later.  Results are 
average of two experiments except for the results recorded for the number of 6-TG" and 2-D-gal  r 
MDAY-D2 colonies obtained after EMS treatment, which represent one experiment only. 
ND, not done. 
in  MDAY-D2  or  TA3  cells  and  compared  the  results  to  those  obtained  after 
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increase in  Oua R,  6-TG  r or  2-D-gait colonies.  However,  5-azacytidine had no 
effect, or only a negligible one, in all cases. Thus, the results confirm those of 
Landolph and Jones (22), and strongly imply that 5-azacytidine is a poor inducer 
of various types of point mutations in mouse tumor cell lines. 
Effects of 5-azacvtidine or EMS on the Levels of 5-Methylcytosine  in DNA of TA3 or 
MDAY-D2  Cells.  As  shown  in  Table  IV,  we  have  made  some  preliminary 
analyses, using HPLC, of the levels of 5-methylcytosine in EMS or 5-azacytidine- 
treated tumor cells. The results show that a decrease in methylcytosine content 
was observed in  5-azacytidine-treated cells (of ~15%),  as expected, though it 
was not as great as we had anticipated based  on the results of others (where 
decreases of about 50% are often observed, e.g., references 23-25). When EMS- 
treated cells were examined, no decrease was detected in MDAY-D2 cells (from 
which turn-  variants are not derived after one-step EMS  treatment).  A  small 
decline was noted in the EMS-treated TA3 cells; however, this was not assessed 
to be statistically significant. 
Discussion 
The  purpose  of these  studies  was  to  determine whether the  treatment  of 
murine tumor cells with 5-azacytidine, like EMS, would result in the derivation 
of clones at high frequency unable to form tumors in normal syngeneic hosts. 
Such selections had previously been reported by Boon and his colleagues (1-6) 
after treatment of routine  tumors with  the alkylating agent  MNNG,  and  by 
ourselves, using EMS (7). While the availability of such so-called tum- variants is 
of considerable interest in itself, the expression of unique tumor antigens by each 
turn- clone (1-6)in conjunction with their derivation at such high frequencies 
raises several important  immunologic and  genetic questions  (11).  One of the 
most obvious of these relates to  the genetic mechanism of the phenomenon. 
Neither the presence of numerous unique tumor antigens nor the extraordinarily 
high  frequency of selections  can  be  explained  on  the  basis  of classic  point 
mutations. 
We therefore turned to a different means of deriving such variants using an 
agent--5-azacytidine--that is only weakly, if at all, mutagenic in eucaryotic cells 
but  which can nevertheless drastically alter gene expression by causing DNA 
TABLE  IV 
Quantitation of DNA 5-Methylcytosine  Content by HPLC in MDAY-D2 or TA3 Cells 
Treated with 5-Azacytidine or EMS* 
Tumor cells  Treatment  % 5-Methylcytosine  % of Control 
MDAY-D2  No treatment  3.90 ±  0.08 
MDAY-D2  3 #M 5-azacytidine  3.20 ±  0.15  82.0 
MDAY-D2  360 #g/ml EMS  4.17 ±  0.15  >100 
TA3  No treatment  3.13 ±  0.11 
TA3  3 #M 5-azacytidine  2.63 ±  0.05  84.0 
TA3  360 #g/ml EMS  3.01  ±  0.02  96.2 
* Cells were labeled with [6-SH]-uridine such that 2 x  10  s cells/ml were incubated with 
2 #Ci/ml uridine for 18 to 24 h. The DNA was extracted and hydrolyzed as described 
by Flateau et ai.  (21) and outlined in Materials and Methods. Cells were labeled 4 d 
after treatment. Results are ± standard deviation from three separate determinations. FROST  ET  AL.  1497 
hypomethylation. The results presented herein describe our findings and suggest 
that the induction of turn- variants by treatment with conventional mutagens 
and 5-azacytidine most likely occurs by a  common mechanism. Thus, we have 
demonstrated that: (a) treatment of tumor cell lines with 5-azacytidine can lead 
to the selection at high frequency of turn- variants; (b) those lines (e.g., TA3) in 
which >80% of the clones express the turn- phenotype after EMS treatment also 
gave rise to >80%  turn- clones after 5-azacytidine treatment. Furthermore, if 
EMS  was  ineffective in  deriving  tum-  clones  from  a  particular  tumor  (e.g., 
MDAY-D2), the same was true after 5-azacytidine treatment; (c) 5-azacytidine- 
induced  turn-  variants  grew  readily  in  nude  mice and  induced  strong CTL 
responses in culture--like the mutagen-induced tum- variants (7). We have also 
obtained  recent evidence which suggests  that  the new  5-azacytidine-induced 
tumor antigens on the turn- clones are--as with EMS-highly polymorphic (Frost, 
unpublished observations). Despite these similarities, we found 5-azacytidine not 
to be significantly mutagenic when tested on our mouse tumor cell lines (Table 
III). This is in stark contrast to the results obtained with EMS. 
In comparing the results using 5-azacytidine or the mutagens EMS or MNNG, 
it is important to note that Wilson and Jones (15) have demonstrated that these 
same mutagens can themselves cause hypomethylation of DNA. Similarly, Boehm 
and Drahovsky (16) have shown that  MNNG can inhibit DNA methylation in 
viable human leukemia cells. These latter authors have also found hypomethyl- 
ation of DNA in  clones of P815  mastocytoma cells derived after treatment in 
vitro with the alkylating agent/carcinogen N-acetoxy-N-2-acetylamino fluorene, 
i.e., AAAF (17). Since 5-azacytidine is a very strong hypomethylating agent but 
such a poor mutagen in eucaryotic cells (22), the most plausible mechanism for 
the observed in Vivo effects reported here is the influence both types of agents 
(i.e., 5-azacytidine or the alkylating agent mutagens) may have on DNA methyl- 
ation levels and patterns, although this remains to be definitively established. In 
this regard our initial analyses of the 5-methylcytosine content of DNA are too 
preliminary to make any conclusions. 
Assessment of overall  levels  of 5-methylcytosine in  DNA  may however be 
uniformative (23) especially.since even small decreases may be sufficient to cause 
transcriptional activation of genes necessary for the expression of turn- pheno- 
type. Other assays, and the examination of many independent clones (17) using 
restriction endonucleases and cDNA gene probes may be necessary to establish 
any clear relationship  between  DNA  hypomethylation and  the  generation of 
turn- variants by mutagens. Thus, until gene probes for the appropriate tumor 
antigens exist, it will be impractical to evaluate this possibility. It should also be 
noted that even in a situation where carcinogen or mutagen treatment of tumor 
cells leads to an overall higher level of 5-methylcytosine content in the cells, many 
of the cells (i.e., clones) in the population may actually be hypornethylated (17). 
Thus, even the small (4%) decrease in  methylcytosine content of EMS treated 
cells may be "significant" in the sense that it may be a  reflection of far greater 
decreases in the many individual clones of the EMS-treated cells. It is also worth 
emphasizing that some authors have reported rapid hypomethylation followed 
by an equally rapid de novo methylation in some 5-azacytidine-induced tumor 
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of methylation levels is far more protracted, e.g.,  10-12 wk in AKR lymphoma 
cells (25). Just where our lines stand in this connection remains to be determined. 
It is therefore clear that there are many complexities to be considered when 
evaluating the methylation status of the treated tumor cell populations. Never- 
theless, we feel that the most plausible hypothesis, at this time, to account for 
our findings is the induction of DNA hypomethylation and subsequent transcrip- 
tional activation of dormant genes coding for tumor antigens. This hypothesis 
also has the attractive feature of providing an explanation for why many turn- 
clones revert to the turn  + phenotype, as described here and reported previously 
by us (7, 26). Such reversions, which are sometimes rapid (26), were difficult to 
explain on the basis of a mutational (i.e,, base sequence change in DNA) origin 
for turn- clones. However, they are much more understandable in the context 
of what is known about the heritability of altered methylation patterns and levels, 
namely that they are somatically inherited with a  high but not perfect fidelity 
(14, 25) so that they can rapidly, or more gradually, return to normal, or near 
normal, levels. Hence the term "stable" should be applied loosely to heritable 
phenotypic changes brought about by hypomethylation. Methylation levels may 
return to normal values over a period of days, weeks, or months, with a resultant 
reversion of certain induced phenotypic traits, as shown recently by Gasson et 
al. (25).  These authors found glucocorticoid-sensitive clones derived from a  5- 
azacytidine-treated steroid-resistant mouse lymphoma line. Such glucocorticoid- 
sensitive  clones were generated at  very high  frequency (10%),  but  gradually 
reverted to a resistant phenotype over a period of 2-3  months in culture (25). 
We  have  noted  similar  sorts  of phenotypic reversions in  our  turn-  variants, 
whether induced by 5-azacytidine or EMS (26). 
We would also like to stress the implications these findings may have in regard 
to possible  "epigenetic" origins of tumor progression  (26-29).  Gradual  hypo- 
methylation of DNA, possibly caused by carcinogen accumulation, chemothera- 
peutic drugs, or local environmental conditions, could result in progressive and 
random activation of many genes,  thus potentially resulting in  neoplastic cell 
populations  of  increasing  diversity  (26,  27,  29).  From  this  population,  the 
emergence of new (and possibly more malignant) subpopulations having heritable 
changes (of varying stability) in  a  particular phenotype, or set of phenotypes, 
could emerge by selection pressures or simple competitive advantages. In some 
cases, the change may render the cells less malignant because of, for example, 
an immunological alteration (as shown here), whereas in other cases, the genes 
activated may make the cells more malignant. Indeed, we have noted that among 
our 5-azacytidine-treated clones which remain tumorigenic, some are actually 
more malignant than the parent tumor, as defined by metastatic aggressiveness 
(26).  L.  Olsson  ~ has reported similar findings.  Thus,  it would appear  that  5- 
azacytidine treatment of tumor cell populations can cause either a short-term or 
long-term heritable decrease in relative aggressiveness (as defined by progressive 
growth  at  the  site  of inoculation),  or  an  increase,  based  on  their  ability  to 
metastasize.  These opposing  changes can  be detected by the testing of many 
Olsson, L., andJ. Forchhammer. Induction of the metastatic phenotype in a mouse tumor model 
by 5-azacytidine and characterization of an antigen associated with metastatic activity. Submitted for 
publication. FROST  ET  AL.  1499 
individual  clones derived from 5-azacytidine-treated  parent tumor cell popula- 
tions. 
Summary 
Highly  immunogenic  "tum-"  (non-tumorigenic  in  normal  syngeneic  hosts) 
clonal variants can be selected from a variety of poorly immunogenic and highly 
tumorigenic mouse cell lines at very high frequencies (e.g., >80%) after treatment 
in  vitro  with  chemical  mutagens  such as ethyl  methanesulfonate  (EMS)  or N- 
methyl-N'-nitro-N-nitrosoguanidine  (MNNG).  We herein  demonstrate  that  the 
same  result  can  be obtained  with  the  poorly mutagenic  cytidine analogue,  5- 
azacytidine, a strong DNA hypomethylating agent. 5-Azacytidine and EMS were 
equally and comparably effective, or ineffective, in inducing turn- variants from 
three different highly tumorigenic mouse cell lines. Like mutagen-induced tum- 
variants,  those obtained after 5-azacytidine treatment  generated  usually strong 
cytolytic T  lymphocyte (CTL) responses in vitro, and could grow in immunosup- 
pressed (nude mouse) hosts. However, pretreatment of the tumor cell lines with 
5-azacytidine  did  not  cause  significant  increases  in  mutations  at  several  inde- 
pendent drug-resistant  gene loci, whereas EMS did.  It is known that  treatment 
of cells with 5-azacytidine can induce transcriptional  activation of "silent" genes 
through  a  reduction of DNA 5-methylcytosine content,  a  process that can also 
be effected by mutagenic DNA alkylating agents such as EMS and MNNG. We 
therefore hypothesize that an  "epigenetic"  mechanism  (DNA hypomethylation) 
leading to activation and expression of genes coding for potential tumor antigens 
is involved in the generation at high frequency of tum- variants after "mutagen" 
treatment.  The implications of these findings to mechanisms of tumor progres- 
sion and the generation of tumor heterogeneity are discussed. 
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